Cardiovascular and Metabolic Disease Center
Mitochondrial Research Affinity Collaboration-Laboratories & Engineering

Home > 0

Mitochondrial physiology in tumourigenesis

  • 작성자한진
  • 작성일2006-05-31 15:01:30
  • 조회수2643
  • 첨부파일첨부파일
063: Mitochondrial physiology in tumourigenesis Date: Tue Mar 28 14:24:01 BST 2006 Mitochondria are energy-producing organelles within cells. Mitochondria consume oxygen (respire) to generate chemical energy. Cells rely on energy to survive, but mitochondria also play a critical role in regulating programmed cell death. This is an active process of cellular self destruction which aims to avoid damage to the organism. Inability of cells to undergo programmed cell death when required is a major contributory factor to cancer. Interestingly, during the 1930s, Otto Warburg described a direct link between mitochondrial physiological functions and cancer development. The 'Warburg effect' or 'aerobic glycolysis' is the observation that many cancer cells consume glucose (a form of sugar) at a much higher rate than expected. This means that although oxygen is abundant and there is no apparent reason for not producing energy by respiration, cancer cells "prefer" to generate energy by a less efficient pathway of accelerated glucose consumption. Warburg actually suggested that defects in respiration may be the sole cause for cancer formation. What may be the advantage of glucose consumption over respiration in cancer cells is not clear. One answer may be a prior adaptation to survival under low oxygen (hypoxia), a condition that most tumours reach as they grow. We I now know that this low oxygen condition facilitates blood vessel growth into the tumour and the spreading of cancer cells to other parts of the body (metastasis). It is possible that accelerated glucose consumption may confer resistance to mitochondria-mediated programmed cell death. The causes for the accelerated glucose production in cancer cells are largely unknown. Along with many other explanations, it is possible that oncogenes (cancer-generating genes) may activate this process. Also, conditions that lead to a state called pseudo-hypoxia activate abnormal glucose consumption. Pseudo-hypoxia is a state in which cells behave as if they are under low oxygen despite the presence of normal oxygen levels and is controlled by a protein complex called hypoxia inducible factor. This complex induces the expression of many genes, some of which increase the activity of glucose consumption. Moreover, several genetic studies have recently shown that some mitochondrial proteins that are important for energy production by the mitochondria are 'tumour suppressors'. This means that certain types of cancer can occur when these proteins are inactivated (due to mutations). Due to the nature of these mutations, energy production in mitochondria is disrupted in these cancer cells and accelerated glucose consumption is observed. Recently, a link between mutations in these tumour suppressor genes and pseudo-hypoxia has been made. Overall, whether glucose consumption is induced by low oxygen (hypoxia) or by pseudo-hypoxia, it is clear that blocking the switch for accelerated glucose consumption by cancer cells could render these cells energy-deprived and cause cell death, a desired outcome of cancer treatment. As mentioned above, the switch to accelerated glucose consumption is largely controlled by hypoxia inducible factor. Our research aims to understand the mitochondrial signals that mediate the activation of hypoxia inducible factor and to block or reverse this process. By doing so, we hope to make cancer cells use less glucose and therefore become more susceptible to programmed cell death as well as incapable of activating blood vessel growth or of spreading to distant parts of the body (metastasis). We have extensively studied the process of hypoxia inducible factor activation due to mitochondrial dysfunction in cell culture. Based on our studies, we have synthesised several new compounds that are capable of preventing and reversing the induction of hypoxia inducible factor. Obviously, we hope that these compounds have the potential to be used in the clinic in the future. The next step towards clinical use must be to analyse the effectiveness of these drugs in tumour models in mice. This study will examine the potential of the new compounds, to further change them, if required, in order to make them more efficient, and to understand the exact mechanism of tumour regression in order to optimize their use with other potential treatments. Two general types of models will be used. The first is based on mice that are defective in their immune system and therefore human cancer cells can be transplanted to these mice. The transplantation is done under the skin, a site that causes minimal discomfort to the animals. Another advantage of this system is that human cancer cells are used and the response to the treatment is more relevant to human cancers. A limitation of the system is that the cells are not genetically defined and therefore which genes lead to cancer development in these cells are unknown. For this reason a second model will be used based on mice that are genetically altered in specific genes that are known to cause cancer in humans. Therefore, mice that develop similar tumours are a good model for studying these human cancers. In both models, we will use the minimal number of animals required to achieve statistically significant results. Moreover, a small pilot experiment will be performed to study the optimal delivery procedure of the drugs in healthy animals and therefore will limit the treatment of tumour-bearing animals only to the most effective method. Furthermore, initial studies of effective doses have been performed in cell culture systems, so a significant amount of valuable information has already been accumulated prior to the experiments with mice. It is also important to mention that in this type of study, animals with tumours are treated early in the process of cancer development to minimise suffering. When the cancer burden is increased, animals are killed in a humane manner to prevent any unnecessary suffering.
Total404 [ page1/27 ]
No. 제목 작성자 작성일 조회수
404 인제대, 과기정통부 ‘2023년도 기초연구실 지원사업’ 선정 2023.09.13 관리자 (web_admin) 2023.09.13 11
403 인제대 교수팀 '돌연사 주범 심부전 원인 규명' 2023.09.13 관리자 (web_admin) 2023.09.13 11
402 2022학년도 인제학술상 수상자 선정 결과 2023.01.05 관리자 2023.01.05 63
401 안전관리 우수연구실 인증 취득 2023.01.05 관리자 2023.01.05 41
400 한진교수 화의자의학상 수상 2023.01.05 관리자 2023.01.05 60
399 이온통로 학회 -Amy 포스터상 수상 2019.01.15 김형규 2019.01.15 2,587
398 센터 겸임교수 조성우 교수 - 한빛사 -JACC Vascular Imaging 2018.12.08 김형규 2018.12.08 2,791
397 2017 IMPACT Symposium 개최 첨부파일 2017.10.31 김보현 2017.10.31 2,588
396 경암바이오유스 2017 첨부파일 2017.08.11 김보현 2017.08.11 2,871
395 KORUS 2017 첨부파일 2017.06.21 김보현 2017.06.21 2,986
394 IMPACT 2016 심포지엄 개최 안내 첨부파일 2016.04.18 관리자 2016.04.18 4,003
393 IMPACT 2015 심포지엄 개최 안내 첨부파일 2015.04.20 서대윤 2015.04.20 2,869
392 2015 중점연구소 성과 전시회 첨부파일 2015.03.31 김형규 2015.03.31 2,462
391 Best Miso Award - 한진 2014.11.04 이정훈 2014.11.04 2,072
390 신진생리학자상 - 김형규 2014.10.29 이정훈 2014.10.29 1,816
처음이전1 2 3 4 5 6 7 8 9 10 다음 마지막